Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Gudisbad is pleased with the results

<< Previous

Bullboard Posts

Next >>

Comment by gudisgoodon Mar 27, 2023 2:38am

111 Views

Post# 35361732

RE:Gudisbad is pleased with the results

I am pleased, or at least pleasantly surprised, by the Q4 results -- well over the guidance.

I would have hoped for a stronger 2023 guidance, though. So I cannot say that I'm "pleased" with that.

But there are positives in the current situation:

the sales of the innovative portfolio are growing,
the business continues to generate a nice cash flow (although I would prefer this to grow as well),
we have the Incyte and Rigel products, plus a bunch of generics, in the pipeline,
we have a very strong balance sheet for any opportunities,
we can buy back our stock at an increasingly attractive valuation.

But yes, I would like to see more growth, more products in the pipeline, more products acquired, more products in-licensed, and so forth. I do believe that all of this will take place, and I do trust the management to make intelligent, rational and risk-averse decisions to get there. It may seem frustratingly slow and quiet at times but that's the price of discipline.